Continuing Pharmacy Education / CE Master List / First-Line Medication Therapy for Type 2 Diabetes: Time for a Change? -RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

First-Line Medication Therapy for Type 2 Diabetes: Time for a Change? -RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

1.      List the American Diabetes Association’s recommended approach to preventing diabetes-related long-term complications.
2.      Identify efficacy and safety data for the newest FDA-approved diabetes medication.
3.      Recall the most recent ADA’s guideline recommendations on medication management of hyperglycemia in type 2 diabetes.

Release and Expiration Dates

Released:  December 16, 2022
Expires:  December 16, 2025

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-22-058-H01-P

Session Code

22RW58-VXK92

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-058-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Khanh Dang, PharmD, CDCES, FNAP
Associate Clinical Professor
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Dang has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Post Test

First-Line Therapy for Type 2 Diabetes: Time for a Change?

1. What is the MOST IMPORTANT therapeutic goal in the management of diabetes?
a. Reduce the A1c to <7%
b. Prevent the development of long-term complications of diabetes
c. Save money from costly treatments

2. What is the most common cause of mortality in people with uncontrolled type 2 diabetes?
a. Complications of atherosclerotic cardiovascular disease
b. Neuropathic pain
c. Diabetic eye disease

3. Tirzepatide belongs to which of the following drug class?
a. GLP-1 receptor agonists
b. Dual GIP/GLP-1 receptor agonist
c. SGLT2 inhibitors

4. Mr. N, the hypothetical patient from the presentation, is prescribed tirzepatide by his PCP. Which of the following would be expected as a COMMON side effect of tirzepatide?
a. Pancreatitis
b. Neuropathic pain
c. Nausea

5. Which of the following statements is TRUE according to the 2023 American Diabetes Association’s diabetes guidelines?
a. Four areas are equally emphasized: glycemic management, weight management, cardiovascular risk factor management, and cardiorenal protection.
b. Glycemic control is the most important therapeutic goal and prescribers should encourage all patient to strive for a HbA1c lower than 6.
c. Prevention of kidney complications of diabetes should be emphasized above other management strategies.

6. Which of the following drug class is associated with the LOWEST potential for weight loss (hint: see the tables at the end of the presentation)?
a. Biguanide (metformin)
b. SGLT2 inhibitors
c. GLP-1 receptor agonists

Handouts

Download

VIDEO